A practical reference on AOD9604: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-03-09 and is reviewed periodically as new material appears.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; visual inspection |
| Solubility | Soluble in water and aqueous buffers | Depends on pH, purity, and counterion |
| Typical storage | -20 °C or below, desiccated | Protect from light; avoid repeated freeze-thaw after reconstitution |
| Common analytical method | Reversed-phase HPLC and mass spectrometry | Purity by HPLC; identity and mass by LC-MS or MALDI-TOF |
| Common synonyms | hGH fragment 176–191; AOD-9604 | Names vary in research and product labeling |
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
===== Long-term effects on CNS ===== Chronic exposure to nicotine induces several molecular changes in neuronal systems, particularly within the mesolimbic dopamine pathway and associated circuits. These adaptations include desensitization and upregulation of nAChRs and downregulation of related enzymes (e.g. class I and II histone deacetylases in the striatum), alterations in transcription factors, and modifications to dopamine synthesis and release. Nicotine binds to presynaptic and postsynaptic nAChRs, leading to initial activation followed by desensitization—a conformational shift rendering receptors temporarily unresponsive. Chronic nicotine exposure promotes upregulation of nAChRs in brain regions like the ventral tegmental area and striatum, with increased receptor density observed within 1–7 days and peaking after 10–14 days in rodent models. Human imaging studies show this upregulation is temporary and returns to baseline levels in nonsmokers by approximately 21 days after smoking cessation but full recovery taking 6-12 weeks. Chronic nicotine use also leads to accumulation of the transcription factor ΔFosB in dopamine D1-type medium spiny neurons of the nucleus accumbens, a process implicated in sustained reward pathway modifications. This elevation is longer-lasting and persists "for weeks and months even when substance use has ceased." Additionally, positron emission tomography (PET) studies indicate reduced presynaptic dopamine synthesis capacity in the striatum of chronic smokers, as measured by 18F-DOPA uptake.
== Method == The RAST is a radioimmunoassay test to detect specific IgE antibodies to suspected or known allergens for the purpose of guiding a diagnosis about allergy. IgE is the antibody associated with Type I allergic response: for example, if a person exhibits a high level of IgE directed against pollen, the test may indicate the person is allergic to pollen (or pollen-like) proteins. A person who has outgrown an allergy may still have a positive IgE years after exposure. The suspected allergen is bound to an insoluble material and the patient's serum is added. If the serum contains antibodies to the allergen, those antibodies will bind to the allergen. Radiolabeled anti-human IgE antibody is added where it binds to those IgE antibodies already bound to the insoluble material. The unbound anti-human IgE antibodies are washed away. The amount of radioactivity is proportional to the serum IgE for the allergen. RASTs are often used to test for allergies when:
Life consists of reproduction with (heritable) variations. NASA defines life as "a self-sustaining chemical system capable of Darwinian evolution." Such a system is complex; the last universal common ancestor (LUCA), presumably a single-celled organism which lived some 4 billion years ago, already had hundreds of genes encoded in the DNA genetic code that is universal today. That in turn implies a suite of cellular machinery including messenger RNA, transfer RNA, and ribosomes to translate the code into proteins. Those proteins included enzymes to operate its anaerobic respiration via the Wood–Ljungdahl metabolic pathway, and a DNA polymerase to replicate its genetic material. The challenge for origin of life researchers is to explain how such a complex and tightly interlinked system could develop by evolutionary steps, as at first sight all its parts are necessary to enable it to function. For example, a cell, whether the LUCA or in a modern organism, copies its DNA with the DNA polymerase enzyme, which is itself produced by translating the DNA polymerase gene in the DNA. Neither the enzyme nor the DNA can be produced without the other. The evolutionary process could have started with molecular self-replication, self-assembly such as of cell membranes, and autocatalysis via RNA ribozymes in an RNA world environment. The transition of non-life to life has not been observed experimentally. Some scientists see both life and the origin of life as aspects of the same process.
=== miRNA === MicroRNAs (miRNAs) have complementary sequences in the 3' UTR and 5' UTR of target mRNAs of protein-coding genes, and cause mRNA cleavage or repression of translational machinery. In diseased vascular vessels, miRNAs are dysregulated and highly expressed. miR-33 is found in cardiovascular diseases. It is involved in atherosclerotic initiation and progression including lipid metabolism, insulin signaling and glucose homeostatis, cell type progression and proliferation, and myeloid cell differentiation. They found in rodents that the inhibition of miR-33 raises HDL-C levels, and miR-33 expression is down-regulated in humans with atherosclerotic plaques. miR-33a and miR-33b are located on intron 16 of human sterol regulatory element-binding protein 2 (SREBP2) gene on chromosome 22 and intron 17 of SREBP1 gene on chromosome 17. miR-33a/b regulates cholesterol/lipid homeostasis by binding in the 3'UTRs of genes involved in cholesterol transport, such as ATP binding cassette (ABC) transporters, and enhances or represses their expression. Studies have shown that ABCA1 mediates cholesterol transport from peripheral tissues to Apolipoprotein-1. It is also important in the reverse cholesterol transport pathway, where cholesterol is delivered from peripheral tissue to the liver, where it can be excreted into bile or converted to bile acids before excretion. Therefore, ABCA1 prevents cholesterol accumulation in macrophages. By enhancing miR-33 function, ABCA1 levels decrease, leading to decreased cellular cholesterol efflux to apoA-1.
The Israelites were named after their ancestor, Jacob/Israel, who was the grandson of Abraham. They were organized into 12 tribes: Reuben, Simeon, Levi, Judah, Dan, Naphtali, Gad, Asher, Issachar, Zebulun, Joseph (or Tribe of Ephraim and Tribe of Manasseh) and Benjamin. After a famine in Canaan, Jacob and his twelve sons migrated to Egypt, where each son became the eponymous progenitor of an Israelite tribe. In Egypt, the Israelites grew from a family into a nation and were enslaved by the Egyptians. They escaped under the leadership of Moses and organized themselves as a kritarchy, where they followed laws given by Moses. Afterwards, the Israelites conquered Canaan and fought with several neighbours until they established a monarchic state. This period is covered by Genesis 12 to 1 Samuel 8.
Sources: en.wikipedia.org
papilledema fibrosis of tendons and joint capsules periosteal thickening and embryotoxicity (see under pregnancy). In preclinical human trials mature megakaryocytes which develop during in vivo treatment with Neumega were ultrastructurally, morphologically, and functionally normal. They also showed a normal life span. In a study in which a single 50 μg/kg subcutaneous dose was administered to eighteen healthy men, the peak serum concentration (Cmax) of 17.4 ± 5.4 ng/mL was reached at 3.2 ± 2.4 h (Tmax) following dosing. The terminal half-life was 6.9 ± 1.7 hours. In a second study in which single 75 μg/kg subcutaneous and intravenous doses were administered to twenty-four healthy subjects, the pharmacokinetic profiles were similar between men and women. The absolute bioavailability of Neumega was >80%. In a study in which multiple, subcutaneous doses of both 25 and 50 μg/kg were administered to cancer patients receiving chemotherapy, Neumega did not accumulate and clearance of Neumega was not altered following multiple doses. Pediatric cancer patients treated with aggressive chemotherapy showed similar pharmakinetic characteristics. In humans treated with oprelvekin on a daily base a twofold increase in fibrinogen levels occurred. Healthy volunteers displayed an increase in von-Willebrand-factor (vWf) activity. Isolated molecules formed under oprelvekin were found to have exact the same multimere structure as the 'normal' factor and were therefore fully functioning.
Log-odds matrices based on the Dayhoff PAM model were commonly used to assess the significance of homology search results, although the BLOSUM matrices have superseded the PAM log-odds matrices in this context because the BLOSUM matrices appear to be more sensitive across a variety of evolutionary distances, unlike the PAM log-odds matrices. The Dayhoff PAM matrix was the source of the exchangeability parameters used in one of the first maximum-likelihood analyses of phylogeny that used protein data and the PAM model (or an improved version of the PAM model called DCMut) continues to be used in phylogenetics. However, the limited number of alignments used to generate the PAM model (reflecting the limited amount of sequence data available in the 1970s) almost certainly inflated the variance of some rate matrix parameters (alternatively, the proteins used to generate the PAM model could have been a non-representative set). Regardless, it is clear that the PAM model seldom has as good of a fit to most datasets as more modern empirical models (Keane et al. 2006 tested thousands of vertebrate, bacterial, and archaeal proteins and they found that the Dayhoff PAM model had the best-fit to at most <4% of the proteins). Starting in the 1990s, the rapid expansion of sequence databases due to improved sequencing technologies led to the estimation of many new empirical matrices (see for a complete list).
== Organisations == Opus Group Berhad, a consortium of several different companies operating under the Opus brand name Opus Energy, an electricity and gas supplier based in the UK Opus College of Business, US
Carlton – The rivalry between Essendon and Carlton is considered one of the strongest in the league. With the teams sharing the record of 16 premierships, both sides are keen to become outright leader, or if out of the finals race, at least ensure the other doesn't. In recent years, the rivalry has thickened, with Carlton beating the 1999 Minor Premiers and premiership favourites by 1 point in the Preliminary Final. Other notable meetings between the two clubs include the 1908, 1947, 1949, 1962 and 1968 VFL Grand Finals and 1993 AFL Grand Final, with some decided by small margins. Of the 6 Grand Finals played out of the two clubs, Essendon has won 3 and Carlton has won 3. Collingwood – In the early days of the VFL, this rivalry grew out of several Grand Final meetings: 1901, 1902 and 1911. The teams didn't meet again in a Grand Final until 1990 when Collingwood won to draw level with the Bombers on 14 premierships and deny the Bombers a chance to join Carlton with 15 flags. Since 1995, the clubs face off against each other annually in the Anzac Day clash, a match which is described as the second biggest of the season (behind only the Grand Final). Being possibly the two biggest football clubs in Victoria, regardless of their position on the ladder, this game always attracts a huge crowd, and it is a match both teams have a great desire to win regardless of either team's season prospects. The rivalry thickened further in 2023 when Collingwood joined Essendon and Carlton with a record 16 premierships.
Sources: en.wikipedia.org
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.
Mass spectrometry, such as LC-MS or MALDI-TOF, confirms the molecular mass and can reveal sequence-related impurities. Reversed-phase HPLC is used for purity, and peptide mapping or amino acid analysis can support sequence identity. No single method establishes every quality attribute.
No. AOD9604 is a short synthetic fragment of the hGH sequence, not the full 191-amino-acid hormone. It lacks the regions that mediate hGH receptor activation and growth-promoting effects. Products labeled as AOD9604 should not be assumed to have the same properties as hGH.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.